1-1 of 1
Vasu Divi
Close
Sort by
Journal Articles

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p

James I. Barnes, Vasu Divi, Adrian Begaye, Russell Wong, Steven Coutre, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert
Journal: Blood Advances
Blood Adv (2018) 2 (15): 1946–1956.
https://doi.org/10.1182/bloodadvances.2017015461
Published: 2018
Includes: Supplemental data